Boehm Bernhard O, Lustig Robert H
Division of Endocrinology, Ulm University, Robert-Koch-Strasse 8, Ulm/Donau, 89070, Germany.
Best Pract Res Clin Gastroenterol. 2002 Jun;16(3):493-509. doi: 10.1053/bega.2002.0320.
Somatostatin (SMS) is a potent inhibitory molecule. It inhibits both exocrine and endocrine secretory functions of the pancreas, suppresses growth hormone secretion and reduces the level of insulin-like growth factor-1. Long-acting somatostatin analogues were currently investigated for potential clinical benefits in two settings: (a) control of hyperinsulinaemia in obesity and (b) control of an excess of pro-angiogenic factors in diabetes-associated retinal complications. In two randomized, controlled trials the long-acting somatostatin analogue octreotide retarded progression of the microvascular complications in pre-proliferative and advanced stages of diabetic retinopathy. Inhibition of the early phase of insulin secretion by use of octreotide in patients with hypothalamic obesity resulted in weight loss and improved quality of life. Efficacy of octreotide correlated to residual beta-cell activity prior to the treatment. Obesity and diabetes mellitus are the most common chronic metabolic disorders in the world. The use of somatostatin analogues addressing the various hormonal imbalances of these disorders may provide a novel concept for their pharmacological treatment.
生长抑素（SMS）是一种强效抑制分子。它抑制胰腺的外分泌和内分泌分泌功能，抑制生长激素分泌并降低胰岛素样生长因子-1的水平。目前正在研究长效生长抑素类似物在两种情况下的潜在临床益处：（a）控制肥胖症中的高胰岛素血症，以及（b）控制糖尿病相关视网膜并发症中促血管生成因子过多的情况。在两项随机对照试验中，长效生长抑素类似物奥曲肽延缓了糖尿病视网膜病变增殖前期和晚期微血管并发症的进展。在下丘脑性肥胖患者中使用奥曲肽抑制胰岛素分泌的早期阶段导致体重减轻和生活质量改善。奥曲肽的疗效与治疗前残余β细胞活性相关。肥胖症和糖尿病是世界上最常见的慢性代谢紊乱疾病。使用生长抑素类似物解决这些疾病的各种激素失衡问题可能为其药物治疗提供一个新的概念。
